Timolol-Acos, eye drops 0.25%, 5ml

Composition

>

1 ml of eye drops contains:

Active ingredients:

timolol maleate (in terms of timolol) – 2.5 mg.

Auxiliary substances:

benzalkonium chloride,

monosubstituted

sodium phosphate dihydrate,12-

water sodium phosphate dihydrate, d/i water.

Pharmacological action

Timolol-AKOS is a non-selective beta-adrenergic blocker with no sympathomimetic activity. When applied topically, it lowers intraocular pressure by reducing the formation of watery moisture and slightly increasing its outflow.

Reducing intraocular pressure does not affect accommodation and pupil size, so there is no deterioration in visual acuity and the quality of night vision does not decrease. The effect is manifested in 20 minutes after instillation, the maximum effect – in 1-2 hours; duration of action-24 hours

. Pharmacokinetics

After instillation of eye drops in the moisture of the anterior chamber of the eye, the time to reach the maximum concentration is 1-2 hours. The Active ingredient enters the systemic bloodstream by absorption through the conjunctiva, nasal mucosa and lacrimal tract. The drug is metabolized by the CYP2D6 enzyme system.

Excretion of metabolites – by the kidneys. In newborns, the concentration of the Active ingredient significantly exceeds its maximum concentration in adult plasma.

Indications

• open-angle glaucoma;
• secondary glaucoma (uveal, aphakic, post-traumatic);
• acute increase in ophthalmotonus;
• closed-angle glaucoma (in combination with myotics).

Use during pregnancy and lactation

The use of Timolol-AKOS during pregnancy is possible only if the intended benefit to the mother exceeds the potential risk to the fetus.

During the use of the drug, breastfeeding should be discontinued.

Contraindications

• bronchial asthma;
• acute and chronic heart failure;
• cardiogenic shock;
• corneal dystrophic diseases;
• rhinitis;
• sinus bradycardia;
• AV block II and III degrees;
• hypersensitivity to the components of the drug.

Side effects

Local reactions: hyperemia of the eyelid skin, burning and itching in the eyes, conjunctival hyperemia, lacrimation or decreased lacrimation, short-term visual acuity, blepharitis, photophobia, corneal epithelial edema, conjunctivitis.

With prolonged use of the drug, it is possible to develop superficial point keratopathy (decrease in corneal transparency), decreased corneal sensitivity, ptosis; rarely-diplopia.

From the cardiovascular system: reduced blood pressure, bradycardia, bradiarrhythmia, AV block, heart failure, cardiac arrest.

Central nervous system disorders: paresthesia, dizziness, headache, drowsiness, hallucinations, transient cerebral circulatory disorders, depression.

From the respiratory system: rhinitis, nasal congestion, shortness of breath, bronchospasm, pulmonary insufficiency.

From the digestive system: nausea, vomiting, diarrhea.

Other services: nosebleeds, muscle weakness, sexual dysfunction, decreased potency, collapse, allergic reactions (including urticaria).

Interaction

Epinephrine and pilocarpine enhance the hypotensive effect of timolol.

When used concomitantly with reserpine, severe bradycardia or hypotension may develop (if necessary, the use of this combination should be carefully monitored).

When used concomitantly with calcium channel blockers or cardiac glycosides, AV conduction, acute left ventricular failure or arterial hypotension may be impaired.

Timolol-AKOS enhances the effect of muscle relaxants (therefore, the drug should be discontinued 48 hours before the expected general anesthesia using peripheral muscle relaxants).

How to take, course of use and dosage

Adults and children over 1 year of age:

• In the lower conjunctival sac of the affected eye (or eyes),1 drop of 0.25% solution is instilled 2 times/day,
• In case of insufficient effectiveness – 1 drop of 0.5% solution 2 times / day.
• After normalization of intraocular pressure – 1 drop of 0.25% solution 1 time/day.

Overdose

When applied topically, no symptoms of overdose are described. Accidental ingestion may cause nausea, vomiting, dizziness, headache, low blood pressure, bronchospasm, and bradycardia.

Treatment: perform symptomatic therapy. If necessary, intravenous isoprenaline is administered to eliminate severe bradycardia or bronchospasm, dobutamine – with the development of arterial hypotension.

Special instructions

During treatment, at least once every 6 months, lacrimation function, corneal integrity, and visual fields should be monitored.

3-4 weeks after the start of therapy, monitoring of the effectiveness of the drug should be carried out.

Remove contact lenses before instillation and put them on no earlier than 15 minutes after the procedure.

Do not put two beta-blockers in your eyes at the same time.

With prolonged use of the drug, the effect may weaken.

When transferring patients to timolol maleate treatment, refractive correction may be required.

Form of production

Timolol-Akos. Eye drops 0.25%

Storage conditions

In a dark place, at a temperature not exceeding 25 °C

Shelf life

2 years

Active ingredient

Timolol

Conditions of release from pharmacies

By prescription

Dosage form

eye drops

Description

For adults as directed by your doctor

Indications

Glaucoma